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Psychostimulants are a diverse group of substances with their main psychomotor effects
resembling those of amphetamine, methamphetamine, cocaine, or cathinone. Due to their
potential as drugs of abuse, recreational use of most of these substances is illegal since
1971 Convention on Psychotropic Substances. In recent years, new psychoactive sub-
stances have emerged mainly as synthetic cathinones with new molecules frequently
complementing the list. Psychostimulant related movement disorders are a known entity
often seen in emergency rooms around the world. These admissions are becoming more
frequent as are fatalities associated with drug abuse. Still the legal constraints of the
novel synthetic molecules are bypassed. At the same time, chronic and permanent move-
ment disorders aremuch less frequently encountered.These disorders frequently manifest
as a combination of movement disorders. The more common symptoms include agita-
tion, tremor, hyperkinetic and stereotypical movements, cognitive impairment, and also
hyperthermia and cardiovascular dysfunction. The pathophysiological mechanisms behind
the clinical manifestations have been researched for decades. The common denominator
is the monoaminergic signaling. Dopamine has received the most attention but further
research has demonstrated involvement of other pathways. Common mechanisms linking
psychostimulant use and several movement disorders exist.
Keywords: psychostimulant abuse, drug induced disorders, drug abuse, movement disorders, psychostimulant
toxicity
INTRODUCTION
Psychostimulants are drugs capable of upregulating higher cortical
activity and produce a transient increase in psychomotor activity.
They have been used to treat a plethora of disorders including
depression, obesity, nasal congestion, mood disorders, attention
deficit hyperactivity disorder (ADHD), etc. However, the use of
these substances has since expanded into recreational abuse in
many countries.
Amphetamine, methamphetamine, cocaine, and cathinone are
considered the more “classical” psychostimulants, but the group
altogether comprises a much larger and constantly increasing
number of substances. The main goal of synthetic substances is
to mimic the psychoactive profile of amphetamine, cocaine, or
other more classic drugs. Most of the abused psychostimulants are
classified as illegal and thus novel synthetic drugs are becoming
available to bypass the legal constraints. A large group of synthetic
cathinones termed “bath salts” is becoming increasingly popular
in several parts of the world (1–3).
Abbreviations: ADHD, attention deficit hyperactivity disorder; CNS, cen-
tral nervous system; DARP-32, dopamine- and cAMP-regulated phosphopro-
tein Mr 32 kDa; DAT, dopamine transporter,; EMCDDA, European Monitoring
Centre for Drugs and Drug Addiction; EU, European Union; fMRI, func-
tional magnetic resonance imaging; GABA, gamma aminobutyric acid; MDMA,
3,4-methylenedioxymethamphetamine; MDVP, 3,4-methylenedioxypyrovalerone;
MRI, magnetic resonance imaging; MRS, magnetic resonance spectroscopy; NET,
norepinephrine transporter; PET, positron emission tomography; SERT, serotonin
transporter; SPECT, single photon emission computed tomography; UK, United
Kingdom; USA, the United States of America; VMAT2, vesicular monoamine
transporter type 2.
Abuse of psychostimulants has been increasing constantly, gen-
erating more emergency room visits, hospital admissions, and
lethalities each year (4, 5). In a recent Swedish study, 83% of
patients admitted to an emergency room due to drug-related
adverse effects screened positive for at least one psychostimulant
substance (6). In UK, there was a significant increase between 2006
and 2010 in the number of individuals in an emergency depart-
ment who reported the use of recreational drugs. Psychostimulants
may cause serious adverse effects including neuroleptic malignant
syndrome, multi-organ failure, parkinsonism–hyperpyrexia syn-
drome, and acute dystonic reaction. Serotonin syndrome with
a high risk for a lethal outcome has been described due to
intoxications after use of 3,4-methylenedioxymethamphetamine
(MDMA), amphetamines, and cocaine (7, 8).
The pathophysiological mechanisms responsible for the effects
of psychostimulants are under increasing interest. Classical sub-
stances have been studied in both humans and animals; however,
the newer drugs are still not well described. In addition to classical
molecular mechanisms by which psychostimulants produce their
effects, including alteration of monoaminergic systems, oxidative
stress, mitochondrial dysfunction, and excitotoxicity, emerging
new aspects have been raised, such as neuroinflammation, blood–
brain barrier damage, and neurogenesis impairment (9). There
are case reports and studies available on underlying mechanisms,
but a solid link is still missing between psychostimulant abuse
and movement disorders. Figure 1 Lists the number of pub-
lished papers on some psychostimulants and demonstrates that
the data concerning newer substances has become available only
in recent years.
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FIGURE 1 | Number of published papers available through the PubMed
database by the end of 2014. The left side of the graph shows that a large
proportion of published papers concerning “new” psychoactive substances
have become available only during the last 5 years (number of papers from
years 2010 and 2014 are shown). The right side of the graph shows the total
number of available papers on a logarithmic scale.
We hereby present a literature review in order to high-
light connections between psychostimulant use and movement
disorders.
PATHOPHYSIOLOGICAL ASPECTS OF MOVEMENT
DISORDERS: A LINK TO PSYCHOSTIMULANTS
Considerable overlap exists between the mechanisms influenced
by psychostimulants and those involved in the pathophysiology of
various movement disorders (Table 1). Movement disorders affect
the control of voluntary and involuntary movements and manifest
as hypokinetic or hyperkinetic disorders including parkinsonism,
tremor, dyskinesias, and myoclonus. Most of these disorders are
either directly or indirectly related to the basal ganglia of the brain.
Evidence of altered cortical function, white matter tract involve-
ment and widespread neural network dysfunction is also becoming
available.
Basal ganglia are a diverse group of interconnected nuclei that
serve an important part in movement execution and the relay
of the associated signals. The classical model proposes a direct
(striatonigral) and indirect (striatopallidal) pathway within basal
ganglia involving subpopulations of striatal projection neurons
(10). The circuits are activated by cortical signals and by regu-
lating gamma aminobutyric acid (GABA) release, they eventually
exert an influence on dopamine-dependent signaling and thus
increase or reduce locomotor activity. Selective contributions of
these pathways have been verified in animals with dopamine- and
cAMP-regulated phosphoprotein Mr 32 kDa (DARP-32) loss in
nigrostriatal neurons in reaction to cocaine (11).
Several neurotransmitter systems are involved with movement
disorders. Altering any of these may lead to motor or cognitive
disorders. The dopamine receptor system is widely spread out
through the central nervous system (CNS). Basal ganglia cells
harbor mainly the D1 and D2 receptors, with other receptor sub-
types represented at lower levels (12). Projections of the dopamine
receptor containing medium spiny neurons also show expression
of specific receptor subtypes. The striatonigral pathway shows
selective D1 while the striatopallidal pathway shows D2 recep-
tor expression (13). Locomotor control is mediated mainly by D1,
D2, and D3 receptors (14). Serotonin is involved in extrapyrami-
dal motor regulation acting through serotonin receptors present
in several cortical areas as well as the striatum. A number of
subtypes of these receptors are known with distinctive distrib-
ution patterns throughout the brain (15). For example, several
receptor subtypes (5HT1F and 5HT3A) are not found in the
caudate, substantia nigra, or globus pallidus and others show
either moderate or low levels of expression within the same
regions in marmoset brains (16). In comparison to dopamine,
serotonin system plays a less important role in motor func-
tioning and is more involved with the cognitive functions. To
some extent, serotonin can regulate dopaminergic motor func-
tion in the nigrostriatal system (17). GABA is the main inhibit-
ing transmitter within the CNS. It exerts its effect through the
GABAA receptor. Sixteen subunits of the receptor have been iden-
tified throughout the CNS with a strong association with motor
control (18).
Abuse of psychostimulants may cause a myriad of move-
ment disorders through their interaction with different
neurotransmitter systems, including dopaminergic, noradrener-
gic, serotonergic, and GABAergic systems (19). Other major mol-
ecular mechanisms include mitochondrial dysfunction, oxidative
stress, and excitotoxicity, and recently suggested new phenomena
of neuroinflammation, neurogenesis, and damaged blood–brain
barrier (9). Chronic drug use leads to persistent adaptive changes
within the reward circuitry that are associated with an impaired
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Table 1 | Examples of psychostimulants and an overview of their toxic effects mediated by monoaminergic systems.
Chemical Neurological adverse
effects (stimulating
effects not included)
Mechanism Targets Brain region
Amphetamine Tremor, choreoathetosis, dystonias,
dyskinesias, ataxia, gait disturbance
Hallucinations
Ischemic infarction, intracerebral
hemorrhage
DA release and reuptake
inhibition, VMAT2
redistribution; cellular toxicity
due to ROS and RNS
production, BBB disruption
DA, DAT, VMAT2,
D2>D1, D3
receptors, 5HT, SERT
STR, VTA, HC
Methamphetamine Choreoathetosis, dystonias, tremor,
ataxia, bruxism, seizures
Behavioral disorders, punding,
psychosis, depression, cognitive
disorder
Stroke
DA release and reuptake
inhibition
DA, DAT, VMAT2, D1,
D2, D3 receptors,
5HT, SERT
STR, VTA, HC
MDMA (Ecstasy) Tremor, dystonias, parkinsonism,
restless legs, bruxism
Seizures
Cognitive dysfunction
5HT and DA release; loss of
5HT-ergic neurons
5HT, SERT, DA, DAT STR
Methylphenidate Anxiety, hyperactivity, euphoria,
stereotypical movements,
psychiatric disturbances
DA release and reuptake
inhibition, DA-ergic neuronal
loss
DA, DAT, D1
receptor, NET
STR, NAc, SN,
striato-orbitofrontal
cortex
Cathinone Impaired memory, depression,
psychosis, insomnia, tremor,
intracerebral hemorrhage
DA release and reuptake
inhibition
DA, DAT, VMAT2, D2
receptor
STR
Mephedrone Increased intracranial pressure,
cerebral edema, seizures, dilated
pupils
Cognitive disorder
Tremor, myoclonus, choreoathetosis
5HT and DA release and
reuptake inhibition, 5HT and
DA-ergic neuronal toxicity
5HT, DA NAc, STR
Methcathinone
(ephedrone)
Parkinsonism, limb and face
dystonias, speech disorder, postural
instability, gait disorder, falls
DA release and reuptake
inhibition
DA, DAT, VMAT2,
NET
STR
Cocaine Tremor, tics,
opsoclonus–myoclonus, dystonias,
orofacial dyskinesias, parkinsonism,
chorea, akathisia, restlessness
Stroke
Seizures
DA release and reuptake
inhibition
DA, DAT VTA, NAc, frontal and
temporal cortex
DA, dopamine; 5HT, serotonin; NE, norepinephrine; DAT, dopamine transporter; SERT, serotonin transporter; NET, norepinephrine transporter; STR, striatum; VTA,
ventral tegmental area; HC, hippocampus; NAc, nucleus accumbens; SN, substantia nigra; VMAT2, vesicular monoamine transporter type 2; ROS, reactive oxygen
species; RNS, reactive nitrogen species; BBB, blood–brain barrier.
cognitive state and neuropsychiatric symptoms, and contribute to
progression and maintenance of addiction (20).
PSYCHOSTIMULANTS – THE “CLASSICS” AND NOVEL
SUBSTANCES, EPIDEMIOLOGY, AND REGULATIONS
Psychostimulants are a very diverse group of substances. The more
common ones have been in routine daily use for centuries. For
example, caffeine and nicotine are still parts of our daily lives.
Chewing of khat leaves (cathinone), dried peyote crowns (mesca-
line), or using paste made of coca leaves (cocaine) was common
practice to create an elevated mood, improve task performance
and motor abilities among tribal members. Cocaine, ampheta-
mine, methamphetamine, MDMA, and methylphenidate can be
classified as “classic” psychostimulants. In more recent years, a
number of new synthetic drugs from different substance groups
have become available. In several reports, these are collectively
described as novel psychoactive substances – a classification based
on the stimulant effects rather than the molecular or cellular basis
of action (2). Polysubstance abuse is common, with a higher
risk for potential harms (21). Psychostimulants used by drivers
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have a serious impact on traffic safety, being associated with fatal
road traffic accidents (22, 23). Stimulants used for treatment
for ADHD may cause toxicity after overdose, producing major
morbidity (24).
Clinically, psychostimulants cause euphoria and agitation, rest-
lessness and hyperactivity, often stereotypical movements, anxiety,
and sometimes appetite suppression. Euphoria may be followed
by depression and discomfort. Sympathomimetic effects present
with hyperthermia, tachycardia and hypertension, sweating, and
palpitations. Neurological, cardiovascular, renal, hepatic, and psy-
chiatric signs and symptoms are often reported as adverse effects
(2, 25). Psychostimulant overdose may cause rhabdomyolysis,
hypertensive crisis, malignant hyperthermia, psychosis, hyperki-
netic abnormal movements, and seizures. Movement disorders
may develop during acute use, chronic drug abuse, or withdrawal,
and may present as transient or permanent (19, 26).
Data concerning the use of psychostimulants are not consis-
tent. The European Union (EU) countries report on the use of
amphetamines, cocaine, and ecstasy, although the reported data
varies largely. High risk of designer drugs to public health has
been revealed in the reports of the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA), and epidemiological
surveys in several populations in Europe and the United States
(US) (27–29). In UK, a total of 1613 drug-related deaths were
reported at 2012, and there has been a slight increase in mor-
tality rates associated with cocaine and ecstasy, as well as novel
psychoactive substances including methcathinone (30).
Studies in UK and USA have shown that despite amendments to
legislation,prohibited substances are available for purchase in large
quantities over the internet. New recreational substances known
as “bath salts” may contain cathinones alone or in different com-
binations, with a high total stimulant content in some products
with variable qualitative composition (31, 32).
Use of “bath salts”(synthetic cathinones) has shown an increase
in recent years: there were 7467 reported cases of intoxication
reported with a male to female ratio of 2.4:1 with most users
being between 20 and 29 years of age. Intentional abuse is the
most common reason for toxicity. A large Central London emer-
gency medical department reported over 200 admissions due
to cocaine toxicity and altogether nearly 50 cases of ampheta-
mine and methamphetamine toxicity among all drug-related cases
admitted in 2010 (33).
An overview of drug use among young people is available from
the web-based Global Drug Survey. In 2013, it received nearly
80,000 responses: 11.7% of participants reported use of amphet-
amines during the past 12 months, 16.4% reported cocaine use,
and 23.4% reported use of MDMA (“ecstasy”). Special atten-
tion was given to the use of “research chemicals and legal highs.”
In countries with more than 1500 responders, their prevalence of
use remained mostly between 5 and 10% (34). Despite the large
number of responders, the study may not be representative of all
psychostimulant due to several social issues and language barrier.
The use of psychostimulants is regulated by the 1971 United
Nations Convention on Psychotropic Substances (35). It prohibits
the use of cathinone and MDMA in Schedule 1, and amphetamine
and methamphetamine in Schedule 2.
AMPHETAMINE AND METHAMPHETAMINE
Amphetamine and methamphetamine are considered the
prototype drugs for describing psychostimulants. Several
amphetamine-like compounds exist naturally, but the first syn-
thesis of amphetamine was likely carried out in Berlin by Lazar
Edeleano in 1887 (36). It was not widely used until 1920s
when the American chemist Gordon Alles resynthesized the drug
and it became a treatment option for asthma. His was also
the first description of the drug’s stimulant effects (37). Later
amphetamine-based nasal congestion remedies became available.
One of the more widely marketed was “Benzedrine,” but others
were also available and used for treatment of mild depression,
narcolepsy, and other disorders (38). Currently, amphetamine
ranks alongside methylphenidate as the most effective drug for
the management of ADHD and narcolepsy (39). Methamphet-
amine was first synthesized in Japan by Nagayoshi Nagai and
taken into military use by several countries for its stimulating
properties (40).
For the illicit drug scene, both amphetamine and methamphet-
amine are relatively easy to produce. Common precursors for their
synthesis are ephedrine and pseudoephedrine. Illicit use has seen
its ups and downs for the past 70–80 years worldwide. Ampheta-
mines are classified as Schedule II drugs in the 1971 United Nations
Convention of Psychotropic substances (35).
Amphetamine-like drugs are used as pills or capsules, pow-
der, or fluid, and can be ingested orally, smoked, insufflated,
or injected intravenously. They cause euphoria but tolerance
develops rapidly. Clinically evident effects of the two drugs are
nearly indistinguishable, but methamphetamine appears to be
a more potent stimulant. Amphetamine and methamphetamine
induce euphoria, increased energy, alertness and libido, agita-
tion and anxiety, increased locomotor activity and stereotypi-
cal movements, as well as hyperthermia, increased heart rate
and blood pressure, vasoconstriction, bronchodilatation, hyper-
glycemia, and suppress appetite. Psychosis, hyperkinesia, seizures,
and coma have been described in emergency patients. Chronic
users may develop behavioral disorders, impulsivity, punding
(non-goal directed repetitive activities), hallucinations, tremor,
choreoathetosis, dystonias, ataxia, and gait disturbances (41–43).
Stereotyped involuntary choreoathetotic hyperkinesias are char-
acteristic in arms, neck and head, and usually disappear during
sleep, while teeth grinding (bruxism) may occur during day and
night. Movement disorders may develop during abuse or absti-
nence, and though they a usually resolve within few days, they
may remain for a long time in some cases, even after the abuse
of amphetamines is stopped. Treatment with benzodiazepines or
neuroleptics may be of benefit (43–45). Choreiform movements
have developed as an adverse effect in the therapeutic setting
of amphetamine used in the treatment of ADHD in adult and
pediatric patients (46, 47).
Amphetamine and methamphetamine may cause strokes, both
ischemic and hemorrhagic, probably associated with an elevated
blood pressure as a major mechanism, or vasoconstriction attrib-
uted to ischemic infarction (48–50). Anxiety is one of the most
prominent psychiatric symptoms in methamphetamine abusers,
associated with poorer outcomes and higher levels of psychiatric
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symptomatology (51). Methamphetamine exposure is linked to
increased rates of depression and suicide attempts (52). Stimu-
lant drugs are known to enhance memory when processing new
information but a recent study in healthy volunteers showed
that dextroamphetamine in therapeutic doses increased errors
during episodic memory retrieval (53). In dependent metham-
phetamine abusers, impairment of learning, executive functions,
and information processing have been demonstrated (54, 55).
Amphetamine intoxication is an increasing burden for emer-
gency departments: in a prospective study, amphetamine-related
presentations comprised 1.2% of attendances, having a major
impact to emergency rooms due to extensive resources required
for patients who are agitated and aggressive, and frequently re-
attend (42). A study on sudden and unexpected deaths associated
with abuse of amphetamine-class drugs, demonstrated intracere-
bral hemorrhage, serotonin syndrome, and heart disease among
causes of death based on forensic autopsies (8).
Regarding the effect to the dopaminergic system, a human
[11C]WIN-35,428-PET study demonstrated a significant reduc-
tion in DAT density in the caudate nucleus and putamen in abusers
of both methamphetamine and methcathinone (142), and an asso-
ciation has been found between DAT loss and methamphetamine-
related psychiatric symptoms (56). Amphetamine treatment simi-
lar to that used for ADHD has been demonstrated to produce brain
dopaminergic neurotoxicity in primates, causing the damage of
dopaminergic nerve endings in the striatum that may also occur
in other disorders with long-term amphetamine treatment (57).
Through findings on the toxicity of methamphetamine toward the
dopaminergic system, its link with neurodegeneration has been
proposed (58, 59).
In experiments, effects of amphetamines in rodents include
hyperthermia and increased locomotor activity. Amphetamine
and methamphetamine act upon the CNS by altering monoamine
dependent signaling. Both molecules are structurally similar to
dopamine and norepinephrine. They induce dopamine release
into the synaptic cleft by affecting synaptic vesicular release, more
specifically vesicular monoamine transporter type 2 (VMAT2)
(60), and altering DAT function by acting as substrates for the
transporter (61). Concurrently, amphetamine and methamphet-
amine lead to serotonin and norepinephrine release by influ-
encing the respective transporters SERT and NET (62, 63). The
ability to reduce striatal DAT and SERT, functional integrity of
dopamine receptors type 1 (D1) and 2 (D2) is critical (64).
Synaptic reuptake of dopamine and serotonin is inhibited at
higher concentrations than norepinephrine (65). Furthermore,
amphetamine and methamphetamine exposure leads to produc-
tion of reactive oxygen and nitrogen species further amplify-
ing their toxic properties (66). At the cellular level, dopamin-
ergic neuron loss within the nigrostriatal pathway has been
demonstrated (67).
3,4-METHYLENEDIOXYMETHAMPHETAMINE (ECSTASY)
3,4-Methylenedioxymethamphetamine, commonly known as
“ecstasy,” was first synthesized in 1914, having been developed for
a use as an appetite suppressant. It has not been used for this pur-
pose but as a “party drug” for recreation since 1980s, being still
one of the most widely used illicit drug among young adults. In a
recent survey, MDMA users reported more dependence symptoms
compared to users of cocaine, mephedrone, or ketamine (68).
3,4-Methylenedioxymethamphetamine is ingested orally or
snorted, causing euphoria, hallucinations, anxiety, restlessness,
and also gait disorders, restless legs, jaw clenching, and lack of
appetite. The effects usually disappear during 24 h but in long-
term use, symptoms like memory impairment, psychosis, depres-
sion, impulsivity, and anxiety may persist. Depression, memory,
and concentration problems, mood fluctuation, anxiety, tremor,
and weight loss have been shown to be associated with the extent
of MDMA use (69, 70). Prenatal exposure to MDMA is a risk
to the developing child: a prospective study demonstrated that
use of MDMA during pregnancy predicts poorer infant men-
tal and motor development at 12 months in a dose-dependent
manner (71).
A range of movement disorders has been described in MDMA
abusers. Abstinent addicts exhibit a large tremor during movement
that may persist for months after cessation of use (72). In chronic
MDMA abusers, dystonic reactions, tremor, and a syndrome with
dyskinesias and stiffness have been described (73–75). Three cases
of parkinsonism have been reported after chronic MDMA use,
with a positive response to the dopaminergic treatment in one
patient (76–78). A possible link between MDMA and Parkinson’s
disease has been proposed but it has not been justified based on
scientific evidence (79).
Serious complications may develop after MDMA abuse. Intrac-
erebral hemorrhage with spastic hemiparesis (80), and two cases
with aplastic anemia that resolved spontaneously (81) have been
described after MDMA exposure. Severe hyperpyrexia, hyper-
kalemia, tremor, sweating, dehydratation, rhabdomyolysis, dis-
seminated intravascular coagulation, and multi-organ failure may
develop similarly to serotonin syndrome and neuroleptic malig-
nant syndrome (7, 82, 83). Hyponatremia and cerebral edema have
been reported as complications of MDMA use causing seizures and
coma possibly leading to a lethal outcome (23, 84). A review on
deaths related to MDMA in England and Wales showed that most
cases with lethal outcome were reported in employed young men
who typically took different drugs together with ecstasy mostly
while partying (85).
3,4-Methylenedioxymethamphetamine exerts its toxic prop-
erties mainly through the serotonin system. Its presence in
the CNS leads to serotonin and, to a lesser extent, dopamine
release. As serotonin is a modulator for different pshychobiolog-
ical functions, the toxic effects of MDMA manifest with deficits
in those functions, including cognition, mood, and psychomo-
tor skills. Neurotoxicity following MDMA is well established
in animal studies showing decrease of SERT and DAT densi-
ties, with concomitant increase in extracellular serotonin and
dopamine concentration (70, 86). 123Iβ-CIT SPECT imaging of
human drug users has demonstrated reduction of SERT bind-
ing in the occipital cortex with the same subjects demonstrating
decreased blood flow in the thalamic region on pharmacological
MRI imaging (87).
METHYLPHENIDATE
Methylphenidate is a short-acting amphetamine-like psychostim-
ulant that was introduced for medical use in 1957. It has been
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used extensively in the treatment of ADHD and adult narcolepsy,
and also prescribed for off-label use against depression and weight
control. The most frequent adverse events have been neuropsy-
chiatric, followed by cardiovascular and cutaneous effects (88).
Methylphenidate is a Schedule II drug, considered to be medically
useful but having a potential risk for abuse and dependence.
Abuse of methylphenidate has been most commonly described
among students with the aim to boost energy and mental per-
formance, improve attention and motivation, and for party-
ing. Methylphenidate is mostly swallowed as pills or snorted
intranasally (89, 90). Studies on effects of methylphenidate on
cognitive function in healthy adults have controversial results,
showing enhancement of cognitive performance in some exper-
iments (91), and no significant effects in others (92). However,
a functional MRI (fMRI) study in ADHD patients in a ran-
domized controlled trial with methylphenidate showed activation
of the frontal cortex and insula that are key areas of cognitive
control (93).
For methylphenidate intoxication, sympathetic nervous sys-
tem stimulation signs are characteristic, including hypertension,
tachycardia, agitation, anxiety, psychosis, headache, and dizziness.
Tremor, tics, chorea, and orofacial dyskinesias have been described
as neurologic side effects of methylphenidate abuse (94, 95). When
injected, methylphenidate may cause serious toxicity resulting in
tissue necrosis, and occasional intra-arterial injections have lead
to the amputation of fingers (96).
In children with ADHD treated with methylphenidate, tics, and
orofacial dyskinesias have been described as adverse events (97,
98). Overdose of methylphenidate has caused mydriasis, tremor,
movement disorders, and seizures (24), but myocardial infarction
and stroke have also been reported as adverse effects at usual doses
of methylphenidate for ADHD (99, 100). Rarely, lethal overdoses
of methylphenidate have been reported (24, 101).
Methylphenidate belongs to the piperidine class, and its struc-
ture and effects are similar to amphetamine. In animal studies, it
has increased the level of dopamine and norepinephrine through
reuptake inhibition of the monoamine transporters but increase of
serotonin is not critical (102). Long-term use of methylphenidate
induced dopamine neuron loss that suggests neurodegenerative
consequences (103). A [18F]FDOPA PET study in healthy subjects
demonstrated that a single methylphenidate challenge increased
striatal dopamine synthesis capacity, and attenuation of dopamine
turnover by methylphenidate is linked to enhanced cognitive
performance (104).
CATHINONES
A diverse group of substances are composed of naturally occur-
ring cathinone and its many structural derivatives. Cathinone is
naturally present in the leaves of Catha edulis (Khat) plants. For
several centuries, humans have used natural amphetamines or
cathinones – like Khat, or ephedrine from various plants of the
Ephedra genus – for their stimulating properties. Chewing of Khat
leaves has been a social and cultural tradition, and is still practiced
in many African and Arabic countries, and also in Somali and
Yemen communities in Europe and North America (105, 106).
“Designer psychostimulants” are often sold as “bath salts,”
“plant food,”“fish food,” or “research chemicals” over the internet.
Some of these substances are relatively easily manufactured with-
out specific laboratory equipment and instructions are readily
available. Cases of intoxication have been increasingly reported
with new“designer”drugs. The production and abuse of cathinone
derivatives is becoming a global epidemic that has raised concerns
as the use of untested novel chemical substances presents potential
hazards (25, 107).
The “classic” cathinones – cathinone, methcathinone, and also
mephedrone – are Schedule II drugs. This has lead to the develop-
ment of synthetic cathinones, also known as “legal” alternatives to
illicit drugs. “Legal highs” are structurally related to amphetamine,
sharing its stimulating and sympathomimetic features: excitement,
euphoria, agitation, increased locomotor activity and stereotypical
movements, anxiety, insomnia, hallucinations, and also creativity,
productivity, and sexual arousal. Adverse effects include dyspho-
ria, aggressiveness, psychosis, lack of concentration, lethargy and
drowsiness, depression and suicidal thoughts, dizziness, and also
tremor, myoclonus, and seizures (105, 108). A survey on the pedi-
atric population with synthetic cathinone exposure showed seizure
complications in 5.5% of cases (109). A rare case of intracerebral
hemorrhage in a cathinone abuser has been described (110). The
use of cathinones may result in cardiovascular consequences and
liver or renal failure, and may lead to death in the most serious
cases (111–114).
Mephedrone (4-methylmethcathinone) is one of the most
popular cathinone derivatives available as a recreational drug
during recent years and having a high abuse and health risk
liability that has urged to classify this as a controlled sub-
stance. The most common routes of mephedrone administration
are snorting and oral ingestion and also intravenous or rec-
tal administrations have been reported. It has stimulant effects
similar to MDMA and cocaine, including increased motor activ-
ity and impulsivity compulsion, psychosis, and sexual disin-
hibition. Several neurological side effects have been reported
such as tremor, stiffness, dizziness, vision disorders, nystag-
mus, and sensory disorders (115–117). Cases of mephedrone
toxicity with increased intracranial pressure, cerebral edema,
seizures, and myoclonus have been reported (115, 118, 119).
Myoclonus and seizures have also been described in methy-
lone abusers, and fatal cases due to mephedrone or methy-
lone toxicity have been reported, in some cases in associ-
ation with multiple drug abuse, manifesting with sympath-
omimetic symptoms (120–122). Increasing use of the novel
designer drug 3,4-methylenedioxypyrovalerone (MDPV) has been
reported, resulting in neurotoxicity with manifestations of tremor,
choreoathetosis, seizures, cerebral edema, dizziness, tinnitus, and
headache (123–125).
The first attempts to isolate the active substance resulted in the
detection of cathine (126). In 1975, cathine’s precursor cathinone
was isolated and found to be the main active substance responsible
for the psychoactive properties of C. edulis leaves. Natural Khat
contains different compounds, including alkaloids, with major
effects on the nervous and gastrointestinal systems. In the CNS,
the target for Khat and cathinone is the dopaminergic system with
widespread involvement of the nucleus accumbens while studies
involving the peripheral nervous system also show effects on the
serotonergic system (105, 127).
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Due to the variety of different molecules their effects vary,
respectively. Cathinones can be grouped by their most promi-
nent effects on monoamine systems into (a) monoamine trans-
porter substrates; (b) DAT-selective transporter substrates; and
(c) non-substrate transporter inhibitors (25). In the pharmacol-
ogy of the different cathinones, considerable differences have been
found: mephedrone, methylone, ethylone, butylone, and naphy-
rone act as non-selective monoamine uptake inhibitors similarly
to cocaine, but at the same time also induced the release of
serotonin similarly to MDMA (128). However, they all have a
specific pharmacological profile; mephedrone has higher brain
penetration, rapid metabolism, and brain clearance than MDMA,
related to high-abuse liability, but the newest compounds have
not undergone thorough preclinical evaluation (117, 129). Cathi-
none and methcathinone act as selective catecholamine uptake
inhibitors and releasers similarly to amphetamine and metham-
phetamine. Pyrovalerone and MDPV are potent and selective
catecholamine transporter inhibitors but not substrate releasers
(128). A study on monoamine-preloaded cells with a new series of
designer cathinones including methedrone, pentylone, ethcathi-
none, pentedrone, and buphedrone, demonstrated that all the
substances were potent norepinephrine uptake inhibitors but dif-
fered in dopamine vs. serotonin transporter inhibition (130). All
synthetic cathinones are capable of increasing locomotor activity
in animals. Other typical signs of action include hyperthermia,
stereotypical behavior, and agitation, although with a different
potential (129, 131, 132). Long-term cognitive and neurochemical
effects of methylone and mephedrone have been shown in animal
experiments (133).
METHCATHINONE (EPHEDRONE)
Methcathinone (ephedrone) is a psychostimulant drug that is
a structural analog of cathinone and methamphetamine. It can
be synthesized from pseudoephedrine containing tablets avail-
able over the counter, in the presence of potassium permanganate
and vinegar. Chemicals and instructions for making the drug are
easily available in several languages on the internet (134). Abuse
of this “designer drug” with street names Cat, Mulka, and Jeff,
has become an increasing public health problem in several East-
ern European countries but single cases have been described in
Western and Southern Europe, and Canada (135–137). The main
reason for its abuse is the amphetamine-like stimulation produced
by methcathinone.
Chronic abuse of this intravenously injectable drug leads to a
levodopa unresponsive parkinsonian syndrome that may develop
after a few months or years of the exposure. The syndrome presents
with parkinsonism, limb and face dystonias, severe speech disor-
ders and postural instability with falls, resembling chronic man-
ganism described in toxic conditions in welders, alloy workers,
patients with chronic liver disease or hereditary conditions causing
manganese overexposure (134). Antiparkinsonian treatment in
these cases is ineffective and the condition may worsen progres-
sively despite discontinuation of drug injections (137, 138).
In active “home made” methcathinone users, serum and hair
manganese levels are extremely high. On T1 weighted MRI images
of active users, symmetrical hyperintensities in the globus pallidus
and substantia nigra have been demonstrated (Figure 2). Other
basal ganglia including the subthalamic nucleus, putamen, cau-
date, and dental nucleus are less frequently involved. The increased
T1 signal disappears after cessation of drug abuse though clinical
manifestations are irreversible (134). On diffusion tensor imaging,
widespread white matter damage has been shown in central areas
and the premotor cortex (139).
This“designer”psychostimulant derived from pseudoephedrine
using potassium permanganate as an oxidant, contains an exces-
sive amount of manganese as a byproduct of the chemical reaction
and has been attributed as a cause for development of the neuro-
logical syndrome (134). The role of methcathinone in the devel-
opment of movement disorder syndrome is not clear but it may
possibly have pathogenic effects on nigral neurons compound-
ing the risk. Both methcathinone and manganese are capable of
interacting with VMAT2. Methcathinone acts as a preferential
catecholamine uptake inhibitor and a dopamine releaser simi-
larly to amphetamine and methamphetamine. The clinical activity
profile is also similar, with manifestations of euphoria, hallucina-
tions, and motor activation (140, 141). In a human PET study,
similar findings have been demonstrated in abstinent methcathi-
none and methamphetamine users, demonstrating a significant
decrease in DAT density in caudate nucleus and putamen (142). In
animal models, multiple administrations of methcathinone have
caused a persistent deficit in dopaminergic system (128, 143).
However, a divergence between in vitro and in vivo properties of
FIGURE 2 |T1 weighted MRI brain scan of a methcathinone abuser, showing high intensity areas of manganese deposits in the basal ganglia. The
deposits disappear after cessation of substance abuse while the extrapyramidal symptoms are irreversible.
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methcathinone has been demonstrated: the drug is very selective
and potent releaser of the catecholamine transporters in vitro, but
elevates both dopamine and serotonin levels in vivo (107).
COCAINE
Cocaine is a potent “classic” psychostimulant. The natural source
of cocaine in the form of coca plant leaves has been known for cen-
turies. In 1859, an active alkaloid cocaine was isolated by Albert
Niemann of Germany (144). For the following half a century, it was
mostly used for medical purposes as a local anesthetic and treat-
ment of depression but thereafter it became increasingly popular
as a drug of abuse. Cocaine is a Schedule II drug.
Clinically evident effects of cocaine are largely dose depen-
dent with correlations to plasma levels. At the same time, large
differences between individuals are present. Clinical manifesta-
tions may vary by the route of administration, purity of sam-
ple, and duration of cocaine abuse. Its stimulant effects man-
ifest as agitation, euphoria, and hyperthermia (145). A variety
of movement disorders have been reported in association with
cocaine abuse. Slow frequency (<8 Hz) hand tremor has been
described in abstinent cocaine abusers (146). Cocaine may induce
tics or exacerbate Tourette’s syndrome (147, 148), and it has
also been reported to cause punding and opsoclonus–myoclonus
(149). Dystonic reaction has been reported in children after acci-
dental exposure to cocaine in their home environments (150).
Neuroleptic malignant syndrome following delirium has rarely
been described in the acute stage, as well as persistent parkin-
sonism following a 3-month abstinence from the drug (151). A
rare syndrome of fulminant encephalopathy with manifestations
of seizures, bradykinesia, myoclonia, and bilateral MRI hyper-
intensities in basal ganglia has been described in HIV-positive
cocaine abusers (152). The use of potassium permanganate in
the processing of coca-leaf extraction can also lead to manganese
intoxication (153).
Neurological complications are more common and severe with
the smokeable alkaloidal form of cocaine known as “crack.”
Cocaine exposure has been reported to cause reversible choreiform
limb movements with restlessness or akathisia, and orofacial dysk-
inesias, referred to as “crack dancing” (154, 155). Usually, chor-
eiform or dystonic movements last from minutes to few days (156,
157), but a case with long-term abnormal movements persisting
after a 20-month abstinent period has been described (158).
Cocaine is the most frequent drug of abuse associated with cere-
brovascular events occurring as a result of cerebral vasospasm,
vasculitis, cardiac arrhythmia, increased platelet aggregation, or
hypertension associated with cerebral autoregulation. Cocaine
may cause ischemic or hemorrhagic strokes by both nasal insuffla-
tion and alkaloidal “crack” smoking routes, but there are a higher
proportion of hemorrhages with nasal use (145). Cardiotoxic-
ity has been a frequent cause for sudden or unexpected death
associated with cocaine as demonstrated by autopsy findings like
coronary artery disease, enlarged heart, and myocarditis (159).
A recent study has provided evidence of the disruptive effects
of cocaine on stimulus–response learning and episodic memory
(160). Cognitive impairment has been associated with connec-
tivity changes in fMRI (161). Prenatal cocaine exposure due to
substance use among pregnant women has been shown to affect
development, behavioral outcomes, and motor performance in
children (162, 163).
Radiological studies of abstinent cocaine abusers demonstrate
increased availability of DAT (164). This may hint at a compen-
satory upregulation of the dopaminergic system in response to
hindered DAT function in the setting of chronic cocaine abuse. D2
and D3 receptor availability is decreased in early abstinence and is
also present at 4 months after cessation of drug use (165) indicat-
ing at a possible permanent structural damage of the dopamine
system. Other means for assessment of structural changes induced
by cocaine use include different MRI-based techniques. Diffu-
sion tensor imaging reveals that white matter pathways in the
frontal lobes of the brain are altered, thus reducing connectiv-
ity between brain areas (166). MRI-based volumetric assessment
of both white and gray matter in the frontal areas also has shown
a decrease in chronic cocaine users (167). fMRI studies of chronic
cocaine abusers have demonstrated a significant motor function
deficit associated with alterations to the dorsal striatum, and an
impaired cortical–striatal connectivity that suggests a fundamen-
tal deficit of cognitive processing (161). Structural abnormalities
showing compromised white matter integrity in cocaine depen-
dence have been associated with functional impairment in decision
making (168).
The main effects of cocaine are produced by its influence on
the dopamine and serotonin signaling, although other systems are
involved. Cocaine leads to increased dopamine release, an effect
shown to be age dependent (169), with extracellular serotonin
concentrations also increased (170). Monoamine release is facil-
itated by cocaine DAT and SERT blocking abilities with similar
binding affinities thus blocking monoamine reuptake (171). A
neuropathological study in chronic cocaine users demonstrated
a threefold increase in α-synuclein levels in the dopamine cell
groups of the substantia nigra and ventral tegmentum (172).
Serotonergic system dysfunction plays an important role in
cocaine sensitivity. SERT and serotonin-1A receptors have been
associated with increased self administration and locomotor activ-
ity in rats. To a greater or lesser extent other serotonin receptor
subtypes are also influenced (173).
CONCLUSION
Psychostimulants are gaining attention as a research subject due
to their popularity among recreational users as the number of
adverse effects increases. The number of substances regarded as
psychostimulants is continuously increasing with new molecules
constantly being added to the nomenclature.
The main effect of these drugs is based on various alterations
they induce in the monoamine systems. The major changes that are
induced include synaptic monoamine release, inhibition of their
reuptake, and changing the signaling that is dependent on respec-
tive transporters. These alterations are mostly reversible when
administration of the causing agent is discontinued. Nonetheless,
there are reports of more permanent damage at molecular and
cellular levels that persist after drug use has ended. As more evi-
dence becomes available, the pathological alterations behind the
mechanisms will be better understood.
In addition to agitation, increased locomotor activity, eupho-
ria, and other psychiatric disturbances, psychostimulant use may
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lead to a variety of acute movement disorders: tremor, gait distur-
bances, parkinsonism, and various hyperkinetic disorders includ-
ing chorea, dyskinesias and dystonias, myoclonus, and akathisia.
Acute syndromes are often witnessed by emergency medical
departments and intensive care units. In acute onset movement
disorders particularly in young people, illicit drug use should
always be contemplated as a possible secondary cause. Fail-
ure to recognize these disorders can lead to missed therapeutic
opportunities and occasional fatalities.
At the same time, psychostimulant related chronic movement
disorders are relatively infrequent. Psychostimulant drugs can
exert a deleterious effect in brain areas also altered in Parkin-
son’s disease and dystonias. The prognosis of long-term side effects
of recreational drugs may be poor, causing irreversible disability.
Spreading abuse of psychostimulants including new psychoactive
designer drugs is a serious public health concern, and physicians
must be aware to recognize these disorders within the social risk
groups.
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